Roche Pharma Day 2025

Roche Pharma Day 2025

Roche Pharma Day 2025 — CHF24bn Pharma, Obesity Push, and R&D Acceleration

Roche’s Pharma Day 2025 showcased CHF24bn HY sales, 17 blockbusters, and an R&D Excellence program that fast-tracks priority assets — with obesity (CT-388, petrelintide), neurology (trontinemab, prasinezumab) and oncology bispecific combos the top strategic bets.